Increase of bone mineral density with sodium fluoride in patients with Crohn's disease

European Journal of Gastroenterology and Hepatology

Volumn 12, Issue 1, 2000, Pages 19-24

  Von Tirpitz, Christian ^b   Klaus, Jochen ^b   Brückel, Joachim ^b   Rieber, Andrea ^b   Scholer, André ^b   Adler, Guido ^b   Böhm, Bernhard O ^b   Reinshagen, Max ^a  

^a UNIVERSITY OF ULM   (Germany)

^b NONE

Author keywords

Bone mass density; Crohn's disease; Osteoporosis; Sodium fluoride

Indexed keywords

ALKALINE PHOSPHATASE; AZATHIOPRINE; CALCIUM CARBONATE; COLECALCIFEROL; FLUORIDE SODIUM; LOSCALCON; MESALAZINE; OSPUR F24; OSTEOCALCIN; PREDNISOLONE; STEROID; UNCLASSIFIED DRUG; VIGANTOLETTEN;

ADD ON THERAPY; ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; CROHN DISEASE; DELAYED RELEASE FORMULATION; DIARRHEA; DIET SUPPLEMENTATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; HUMAN; LUMBAR SPINE; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033965036     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200012010-00005     Document Type: Article

References (48)

1. 1 Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995; 10:250-256.
2. 2 Bjarnason I, Macpherson A, Mackintosh C, Buxton Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40:228-233.
3. 3 Roux C, Abitbol V, Chaussade S, Kolta S, Guillement S, Dougados M, et al. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporosis Int 1995; 5:156-160.
4. 4 Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med 1996; 239:131-137.
5. 5 von Tirpitz C, Pischulti G, Klaus J, Rieber A, Brückel B, Böhm BO, et al. Pathologische Knochendichte bei chronisch entzündlichen Darmerkrankungen - Prävalenz und Risikofaktoren. Z Gastroenterol 1999; 37:5-12.
6. 6 Driscoll RH, Jr, Meredith SC, Sitrin M, Rosenberg IH. Vitamin deficiency and bone disease in patients with Crohn's disease. Gastroenterology 1982; 83:1252-1258.
7. 7 Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997; 40:313-319.
8. 8 Motley RJ, Crawley EO, Evans C, Rhodes J, Comston JE. Increased rate of spinal trabecular bone loss in patients with inflammatory bowel disease. Gut 1988; 29:1332-1336.
9. 9 Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37:71-76.
10. 10 Pearce G, Tabensky DA, Delmas PD, Baker HW, Seeman E. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 1998; 83:801-806.
11. 11 Andreassen H, Rungby J, Dahlerup JF. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 1997; 32:1247-1255.
12. 12 MacDonald BR, Gowen M. Cytokines and bone. Br J Rheumatol 1992; 31:149-155.
13. 13 Menge F, Karmatschek M, Caspary WF, Stein J. Increased serum levels of bone sialoprotein (BSP) in patients with inflammatory bowel disease (IBD). Role of proinflammatory cytokines [Abstract]. Gastroenterology 1998; 114:A4248.
14. 14 Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998; 93:1483-1490.
15. 15 Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995; 7:609-614.
16. 16 Hui SL, Slemenda CW, Johnston CC Jr. Baseline measurement of bone mass predicts fractures in white women. Ann Intern Med 1989; 111:355-361.
17. 17 Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology 1997; 112:1710-1713.
18. 18 Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Procock N, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993; 328:1747-1752.
19. 19 Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N Engl J Med 1997; 337:670-676.
20. 20 Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W, et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 1996; 10:777-786.
21. 21 Josse RG. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women. Can Med Assoc J 1996; 155:929-934.
22. 22 Young R, May H, Murphy S, Grey C, Compston JE. Rates of bone loss in peri-and postmenopausal women: a 4 year, prospective, population-based study. Clin Sci 1996; 91:307-312.
23. 23 Body JJ. Calcitonin for prevention and treatment of postmenopausal osteoporosis. Clin Rheumatol 1995; 14(suppl 3): 18-21.
24. 24 Ellerington MC, Hillard TC, Whitcroft SI, Marsh MS, Lees B, Banks LM, et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 1996; 59:6-11.
25. 25 Fleisch JA. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med 1997; 29:55-62.
26. 26 Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333:1437-1443.
27. 27 Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. Intermittant etidronate therapy to prevent corticoid-induced osteoporosis. N Engl J Med 1997; 337:382-387.
28. 28 Pak CY, Sakhaee K, Adams Huet B, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med 1995; 123:401-408.
29. 29 Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322:802-809.
30. 30 Kleerekoper M, Mendlovic DB. Sodium fluoride therapy of postmenopausal osteoporosis. Endocr Rev 1993; 14:312-323.
31. 31 Pak CY, Sakhaee K, Gallagher C, Parcel C, Peterson R, Zerwekh JE, et al. Attainment of therapeutic fluoride levels in serum without major side effects using a slow-release preparation of sodium fluoride in postmenopausal osteoporosis. J Bone Miner Res 1986; 1:563-571.
32. 32 Pouilles JM, Tremollieres F, Causse E, Louvet JP, Ribot C. Fluoride therapy in postmenopausal osteopenic women: effect on vertebral and femoral bone density and prediction of bone response. Osteoporosis Int 1991; 1:103-109.
33. 33 Seibel MJ, Baylink DJ, Farley JR, Epstein S, Yamauchi M, Eastell R, et al. Basic science and clinical utility of biochemical markers of bone turnover -a congress report. Exp Clin Endocrinol Diabetes 1997; 105:125-133.
34. 34 Dambacher MA, Ittner J, Ruegsegger P. Long-term fluoride therapy of postmenopausal osteoporosis. Bone 1986; 7:199-205.
35. 35 Robinson JR, Krzywicki T, Almond L, Al-Azzawi F, Abrams K, Iqbal SJ, Mayberry JF. Effect of a low-impact exercise program on bone mineral density in Crohn's disease: a randomized controlled trial. Gastroenterology 1998; 115:36-41.
36. 36 Kanis JA, Melton J, Christiansen C, Johnston CC, Khaltev N. The diagnosis of osteoporosis, J Bone Miner Res 1994; 9:1137-1141.
37. 37 WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Tech Rep Ser (Geneva) 1994; vol. 843, pp. 1-129.
38. 38 Ringertz H, Marshall D, Johansson C, Johnell O, Kullenberg RJ, Ljunghall S, et al. Principles and conditions for measuring bone mineral content. J Intern Med 1997; 241(suppl 739):47-51.
39. 39 Taves DR. New approach to the treatment of bone disease with fluoride. Fed Proc 1970; 29:1185-1187.
40. 40 Pak CY, Sakhaee K, Parcel C, Poindexter J, Adams B, Bahar A, Beckley R. Fluoride bioavailability from slow-release sodium fluoride given with calcium citrate. J Bone Miner Res 1990; 5:857-862.
41. 41 Pak CY, Sakhaee K, Zerwekh JE, Parcel C, Peterson R, Johnson K. Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures. J Clin Endocrinol Metab 1989; 68:150-159.
42. 42 Hansson T, Roos B. The effect of fluoride and calcium on spinal bone mineral content: a controlled, prospective (3 years) study. Calcif Tissue Int 1987; 40:315-317.
43. 43 Hodsman AB, Drost DJ. The response of vertebral bone mineral density during the treatment of osteoporosis with sodium fluoride. J Clin Endocrinol Metab 1989; 69:932-938.
44. 44 Duursma SA, Glerum JH, van Dijk A, Bosch R, Kerkhoff H, van Putten J, et al. Responders and nonresponders after fluoride therapy in osteoporosis. Bone 1987; 8:131-136.
45. 45 Kleerekoper M, Balena R. Fluorides and osteoporosis. South Med J 1992; 85(suppl 2):34-42.
46. 46 Parfitt AM. The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res 1982; 4:1-6.
47. 47 Pak CY, Sakhaee K, Rubin C, Zerwekh JE. Sustained-released sodium-fluoride in the management of established osteoporosis. Am J Med Sci 1997; 313:23-32.
48. 48 Zerwekh JE, Hagler HK, Sakhaee K, Gottschalk F, Peterson RD, Pak CY. Effect of slow-release sodium fluoride on cancellous bone histology and connectivity in osteoporosis. Bone 1994; 15:691-699.